Review



human chronic myeloid leukemia cml cell line k562  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC human chronic myeloid leukemia cml cell line k562
    Human Chronic Myeloid Leukemia Cml Cell Line K562, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 11118 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/pm42958942-107-6-18
    Average 99 stars, based on 11118 article reviews
    human chronic myeloid leukemia cml cell line k562 - by Bioz Stars, 2026-11
    99/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial
    Article Snippet: Experiments were conducted with human NK cells primed overnight with recombinant human interleukine‐15 (IL‐15) (50 ng/mL) (Sigma) in RPMI‐1640 complete medium supplemented with 10% Foetal Bovine Serum (FBS) to ensure their proper expression of human NK cells activating receptors and functionality. .. Cytokine‐activated human NK cells were cultured in the presence of human K562 cells (ATCC, #CCL‐243; positive control), or PMA/ionomycin (Beckman Coulter, # C11102 ; positive control), PBS 1X (50 μL; vehicle control) or final product (50 μL); and labelled with an anti‐CD107a‐APC antibody (Miltenyi Biotec, #130‐111‐847). .. After 18 h, cells were harvested, washed and stained with CD16‐PE, CD56‐PE, CD8‐APC Vio770, CD4 Viogreen specific antibodies and 7‐AAD (Miltenyi Biotec), and the expression of CD107a was analysed on CD16 + CD56 + human NK cells using a MQ10 Flow Cytometer (Miltenyi Biotec).

    Article Title: Histone H3K27 methylation states are sequentially catalyzed in cycling cells
    Article Snippet: .. Human K562 cells (ATCC, Manassas, VA, Catalog #CCL-243) were cultured following the supplier’s protocol. ..

    Article Title: Spatial mapping of RNA turnover kinetics and regulatory landscapes of mRNA stability in the mammalian brain
    Article Snippet: .. Human K562 cells (ATCC, CCL-243) were cultured in RPMI media supplemented with 10% fetal bovine serum (FBS, Sigma, F6178). ..

    Article Title: Highly sensitive and scalable time-resolved RNA sequencing in single cells with scNT-seq2
    Article Snippet: .. Human K562 cells (ATCC, CCL-243) were cultured in RPMI media supplemented with 10% Fetal Bovine Serum (Sigma, F6178). ..

    Article Title: CoCUT&Tag maps linked chromatin states at single-molecule, single-cell resolution
    Article Snippet: .. Human K562 cells (ATCC, Manassas, VA, Catalog #CCL-243) were cultured following the supplier’s protocol in a Sanyo cell culture incubator with standard settings (37°C with 5% CO 2 ). ..

    Article Title: Chromatin-bound U2AF2 splicing factor ensures exon inclusion.
    Article Snippet: Human K562 cells (ATCC, Manassas, VA, Catalog #CCL-243) were cultured following the supplier’s protocol. .. Human K562 cells (ATCC, Manassas, VA, Catalog #CCL-243) were cultured following the supplier’s protocol. .. The transcription inhibitors used were Triptolide at 10 μM (Selleckchem, Catalog #S3604), Flavopiridol hydrochloride hydrate at 1 μM (Sigma-Aldrich, Catalog #FL3055), Actinomycin D at 5 μg/ml (Sigma-Aldrich, Catalog #A9415).

    Positive Control:

    Article Title: GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial
    Article Snippet: Experiments were conducted with human NK cells primed overnight with recombinant human interleukine‐15 (IL‐15) (50 ng/mL) (Sigma) in RPMI‐1640 complete medium supplemented with 10% Foetal Bovine Serum (FBS) to ensure their proper expression of human NK cells activating receptors and functionality. .. Cytokine‐activated human NK cells were cultured in the presence of human K562 cells (ATCC, #CCL‐243; positive control), or PMA/ionomycin (Beckman Coulter, # C11102 ; positive control), PBS 1X (50 μL; vehicle control) or final product (50 μL); and labelled with an anti‐CD107a‐APC antibody (Miltenyi Biotec, #130‐111‐847). .. After 18 h, cells were harvested, washed and stained with CD16‐PE, CD56‐PE, CD8‐APC Vio770, CD4 Viogreen specific antibodies and 7‐AAD (Miltenyi Biotec), and the expression of CD107a was analysed on CD16 + CD56 + human NK cells using a MQ10 Flow Cytometer (Miltenyi Biotec).

    Control:

    Article Title: GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial
    Article Snippet: Experiments were conducted with human NK cells primed overnight with recombinant human interleukine‐15 (IL‐15) (50 ng/mL) (Sigma) in RPMI‐1640 complete medium supplemented with 10% Foetal Bovine Serum (FBS) to ensure their proper expression of human NK cells activating receptors and functionality. .. Cytokine‐activated human NK cells were cultured in the presence of human K562 cells (ATCC, #CCL‐243; positive control), or PMA/ionomycin (Beckman Coulter, # C11102 ; positive control), PBS 1X (50 μL; vehicle control) or final product (50 μL); and labelled with an anti‐CD107a‐APC antibody (Miltenyi Biotec, #130‐111‐847). .. After 18 h, cells were harvested, washed and stained with CD16‐PE, CD56‐PE, CD8‐APC Vio770, CD4 Viogreen specific antibodies and 7‐AAD (Miltenyi Biotec), and the expression of CD107a was analysed on CD16 + CD56 + human NK cells using a MQ10 Flow Cytometer (Miltenyi Biotec).



    Similar Products

    99
    ATCC human chronic myeloid leukemia cml cell line k562
    Human Chronic Myeloid Leukemia Cml Cell Line K562, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/pm42958942-107-6-18
    Average 99 stars, based on 1 article reviews
    human chronic myeloid leukemia cml cell line k562 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human erythroid k562 cells
    Circulating NK cell degranulation and angiogenic capabilities in T2DM patients with neuropathy and controls. Multicolor flow cytometry analysis for circulating NK cell degranulation activity against <t>K562</t> target cells, showing the frequency of CD107 + circulating NK cells (A) Sample size n = 19–20. Data are shown as mean ± SEM, non‐parametric two‐sample Wilcoxon test, * p < 0.05. Representative dot plots and gating strategies used for the degranulation assay. Singlets were gated on SSC‐A/SSC‐H plot, followed by morphology identification of lymphocytes (SSC‐A/FSC‐A). NK cells were identified as CD3 − CD56 + cells, and CD107a + cells were gated to evaluate their degranulation capabilities. (B) HC: Nondiabetic controls; N: T2DM patients with neuropathy. Graphs of the average expression (2 −ΔCt ) of IFN‐γ (C), CD96 (D), and TIM3 (E) measured by real‐time Q‐PCR of sorted NK cells from N patients and nondiabetic controls. Sample size n = 6–7. EC tube network formation assay on Matrigel. HUVECs exposed to CM of FACS‐sorted NK from healthy control (CM NK‐HC) and T2DM patients with neuropathy (CM NK–N), for 16 h. Representative images (5× magnification) (F) and quantification of the number of segments (G), number of branches (H), total segments length (I), and total branches length (L). Sample size n = 3. Data are presented as mean ± SD, non‐parametric Student t test, * p < 0.05. Spheroid collagen invasion assay. Representative images (5× magnification) (M) of spheroid collagen invasion area on HUVECs exposed for 24 h to CM of FACS‐sorted NK from healthy control and T2DM patients with neuropathy measured as fold change vs. T0. Data are shown as the mean ± SD of 10 different spheroids for HC group and 12 different spheroids for the N group ( n = 10 and 12 biological replicates) (N). Non‐parametric Student t test (*** p < 0.001). The assays were performed on subsets of samples with sufficient PBMCs and sorted NK availability.
    Human Erythroid K562 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/pmc13676027-102-1-5
    Average 99 stars, based on 1 article reviews
    human erythroid k562 cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human erythroleukemia cells k562
    Circulating NK cell degranulation and angiogenic capabilities in T2DM patients with neuropathy and controls. Multicolor flow cytometry analysis for circulating NK cell degranulation activity against <t>K562</t> target cells, showing the frequency of CD107 + circulating NK cells (A) Sample size n = 19–20. Data are shown as mean ± SEM, non‐parametric two‐sample Wilcoxon test, * p < 0.05. Representative dot plots and gating strategies used for the degranulation assay. Singlets were gated on SSC‐A/SSC‐H plot, followed by morphology identification of lymphocytes (SSC‐A/FSC‐A). NK cells were identified as CD3 − CD56 + cells, and CD107a + cells were gated to evaluate their degranulation capabilities. (B) HC: Nondiabetic controls; N: T2DM patients with neuropathy. Graphs of the average expression (2 −ΔCt ) of IFN‐γ (C), CD96 (D), and TIM3 (E) measured by real‐time Q‐PCR of sorted NK cells from N patients and nondiabetic controls. Sample size n = 6–7. EC tube network formation assay on Matrigel. HUVECs exposed to CM of FACS‐sorted NK from healthy control (CM NK‐HC) and T2DM patients with neuropathy (CM NK–N), for 16 h. Representative images (5× magnification) (F) and quantification of the number of segments (G), number of branches (H), total segments length (I), and total branches length (L). Sample size n = 3. Data are presented as mean ± SD, non‐parametric Student t test, * p < 0.05. Spheroid collagen invasion assay. Representative images (5× magnification) (M) of spheroid collagen invasion area on HUVECs exposed for 24 h to CM of FACS‐sorted NK from healthy control and T2DM patients with neuropathy measured as fold change vs. T0. Data are shown as the mean ± SD of 10 different spheroids for HC group and 12 different spheroids for the N group ( n = 10 and 12 biological replicates) (N). Non‐parametric Student t test (*** p < 0.001). The assays were performed on subsets of samples with sufficient PBMCs and sorted NK availability.
    Human Erythroleukemia Cells K562, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/10__3390_slash_molecules31203581-265-19-27
    Average 99 stars, based on 1 article reviews
    human erythroleukemia cells k562 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC k562 human chronic myelogenous leukemia cells
    (A) Representative immunoblot analysis of G9a, WIZ, BCL11A, H3K9me2 and H3K9me3 in HUDEP-2 whole cell extract, soluble, and chromatin-bound fractions from cells treated with vehicle (Veh), hydroxyurea (HU), or aphidicolin (APH) as indicated. Tubulin serves as a loading control for the soluble fraction and total H3 as a loading control for the chromatin-bound fraction, while Ser345-phosphorylated CHEK1 (p-Chk1) is a marker of DNA replication stress. (B–C) Quantification of immunoblot signals from (A) along with other replicates (n = 3, blots not shown) for (B) whole cell extract and (C) soluble and chromatin-bound fractions as indicated. Signal intensities are normalized to indicated loading controls. Statistical significance was determined via two-way ANOVA and p-values > 0.05 are indicated as ns (not significant). (D) Representative immunoblot of FLAG and G9a signal in parental HUDEP-2 cells, HUDEP-2 cells transduced with a FLAG-G9a overexpression construct containing a puromycin resistance gene prior to selection, and similarly transduced HUDEP-2 cells selected with puromycin for 72 hr (hereafter referred to as G9a OE cells). β-actin serves as a loading control. (E) Quantification of the representative immunoblot shown in (D). FLAG and G9a signal is normalized to their corresponding β-actin loading control. (F) EHMT2 (G9a) RNA transcript levels in parental HUDEP-2 cells and G9a OE HUDEP-2 cells (n=3). p-value was calculated using Student’s t-test. (G) Bar plot comparing the increase in the percent of mCherry+ cells following treatment of parental and G9a OE HUDEP-2 cells with either HU or aphidicolin (APH) as indicated (n=3). p-values were calculated using Student’s t-test. (H) Genome tracks for H3K9ac, H3K9me2, and H3K9me3 ChIP-seq signal in <t>K562</t> cells, data derived from previously published work . Highlighted regions denote globin gene clusters and the locus control region (LCR) as indicated. (I) EHMT2 (G9a) RNA transcript levels measured by qRT-PCR in parental K562 cells and K562 G9a OE cells as indicated. qRT-PCR signal is normalized to PPIB and RPLP0 . P-values were calculated using Student’s t-test (n=3). (J) HBG1/2 RNA transcript levels measured by qRT-PCR in parental K562 cells and G9a OE K562 cells with and without HU treatment. qRT-PCR signal is normalized to PPIB and RPLP0. P-values were calculated using Student’s t-test (n=3).
    K562 Human Chronic Myelogenous Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/bio_rxiv__64898__2026__10__06__757090-236-0-6
    Average 99 stars, based on 1 article reviews
    k562 human chronic myelogenous leukemia cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human leukemic cell line k562
    (A) Representative immunoblot analysis of G9a, WIZ, BCL11A, H3K9me2 and H3K9me3 in HUDEP-2 whole cell extract, soluble, and chromatin-bound fractions from cells treated with vehicle (Veh), hydroxyurea (HU), or aphidicolin (APH) as indicated. Tubulin serves as a loading control for the soluble fraction and total H3 as a loading control for the chromatin-bound fraction, while Ser345-phosphorylated CHEK1 (p-Chk1) is a marker of DNA replication stress. (B–C) Quantification of immunoblot signals from (A) along with other replicates (n = 3, blots not shown) for (B) whole cell extract and (C) soluble and chromatin-bound fractions as indicated. Signal intensities are normalized to indicated loading controls. Statistical significance was determined via two-way ANOVA and p-values > 0.05 are indicated as ns (not significant). (D) Representative immunoblot of FLAG and G9a signal in parental HUDEP-2 cells, HUDEP-2 cells transduced with a FLAG-G9a overexpression construct containing a puromycin resistance gene prior to selection, and similarly transduced HUDEP-2 cells selected with puromycin for 72 hr (hereafter referred to as G9a OE cells). β-actin serves as a loading control. (E) Quantification of the representative immunoblot shown in (D). FLAG and G9a signal is normalized to their corresponding β-actin loading control. (F) EHMT2 (G9a) RNA transcript levels in parental HUDEP-2 cells and G9a OE HUDEP-2 cells (n=3). p-value was calculated using Student’s t-test. (G) Bar plot comparing the increase in the percent of mCherry+ cells following treatment of parental and G9a OE HUDEP-2 cells with either HU or aphidicolin (APH) as indicated (n=3). p-values were calculated using Student’s t-test. (H) Genome tracks for H3K9ac, H3K9me2, and H3K9me3 ChIP-seq signal in <t>K562</t> cells, data derived from previously published work . Highlighted regions denote globin gene clusters and the locus control region (LCR) as indicated. (I) EHMT2 (G9a) RNA transcript levels measured by qRT-PCR in parental K562 cells and K562 G9a OE cells as indicated. qRT-PCR signal is normalized to PPIB and RPLP0 . P-values were calculated using Student’s t-test (n=3). (J) HBG1/2 RNA transcript levels measured by qRT-PCR in parental K562 cells and G9a OE K562 cells with and without HU treatment. qRT-PCR signal is normalized to PPIB and RPLP0. P-values were calculated using Student’s t-test (n=3).
    Human Leukemic Cell Line K562, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/pm42843443-51-15-21
    Average 99 stars, based on 1 article reviews
    human leukemic cell line k562 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human chronic myelogenous leukemia cell line k562
    (A) Representative immunoblot analysis of G9a, WIZ, BCL11A, H3K9me2 and H3K9me3 in HUDEP-2 whole cell extract, soluble, and chromatin-bound fractions from cells treated with vehicle (Veh), hydroxyurea (HU), or aphidicolin (APH) as indicated. Tubulin serves as a loading control for the soluble fraction and total H3 as a loading control for the chromatin-bound fraction, while Ser345-phosphorylated CHEK1 (p-Chk1) is a marker of DNA replication stress. (B–C) Quantification of immunoblot signals from (A) along with other replicates (n = 3, blots not shown) for (B) whole cell extract and (C) soluble and chromatin-bound fractions as indicated. Signal intensities are normalized to indicated loading controls. Statistical significance was determined via two-way ANOVA and p-values > 0.05 are indicated as ns (not significant). (D) Representative immunoblot of FLAG and G9a signal in parental HUDEP-2 cells, HUDEP-2 cells transduced with a FLAG-G9a overexpression construct containing a puromycin resistance gene prior to selection, and similarly transduced HUDEP-2 cells selected with puromycin for 72 hr (hereafter referred to as G9a OE cells). β-actin serves as a loading control. (E) Quantification of the representative immunoblot shown in (D). FLAG and G9a signal is normalized to their corresponding β-actin loading control. (F) EHMT2 (G9a) RNA transcript levels in parental HUDEP-2 cells and G9a OE HUDEP-2 cells (n=3). p-value was calculated using Student’s t-test. (G) Bar plot comparing the increase in the percent of mCherry+ cells following treatment of parental and G9a OE HUDEP-2 cells with either HU or aphidicolin (APH) as indicated (n=3). p-values were calculated using Student’s t-test. (H) Genome tracks for H3K9ac, H3K9me2, and H3K9me3 ChIP-seq signal in <t>K562</t> cells, data derived from previously published work . Highlighted regions denote globin gene clusters and the locus control region (LCR) as indicated. (I) EHMT2 (G9a) RNA transcript levels measured by qRT-PCR in parental K562 cells and K562 G9a OE cells as indicated. qRT-PCR signal is normalized to PPIB and RPLP0 . P-values were calculated using Student’s t-test (n=3). (J) HBG1/2 RNA transcript levels measured by qRT-PCR in parental K562 cells and G9a OE K562 cells with and without HU treatment. qRT-PCR signal is normalized to PPIB and RPLP0. P-values were calculated using Student’s t-test (n=3).
    Human Chronic Myelogenous Leukemia Cell Line K562, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/pmc13759699-69-8-19
    Average 99 stars, based on 1 article reviews
    human chronic myelogenous leukemia cell line k562 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    k-562  (ATCC)
    99
    ATCC k-562
    (A) Representative immunoblot analysis of G9a, WIZ, BCL11A, H3K9me2 and H3K9me3 in HUDEP-2 whole cell extract, soluble, and chromatin-bound fractions from cells treated with vehicle (Veh), hydroxyurea (HU), or aphidicolin (APH) as indicated. Tubulin serves as a loading control for the soluble fraction and total H3 as a loading control for the chromatin-bound fraction, while Ser345-phosphorylated CHEK1 (p-Chk1) is a marker of DNA replication stress. (B–C) Quantification of immunoblot signals from (A) along with other replicates (n = 3, blots not shown) for (B) whole cell extract and (C) soluble and chromatin-bound fractions as indicated. Signal intensities are normalized to indicated loading controls. Statistical significance was determined via two-way ANOVA and p-values > 0.05 are indicated as ns (not significant). (D) Representative immunoblot of FLAG and G9a signal in parental HUDEP-2 cells, HUDEP-2 cells transduced with a FLAG-G9a overexpression construct containing a puromycin resistance gene prior to selection, and similarly transduced HUDEP-2 cells selected with puromycin for 72 hr (hereafter referred to as G9a OE cells). β-actin serves as a loading control. (E) Quantification of the representative immunoblot shown in (D). FLAG and G9a signal is normalized to their corresponding β-actin loading control. (F) EHMT2 (G9a) RNA transcript levels in parental HUDEP-2 cells and G9a OE HUDEP-2 cells (n=3). p-value was calculated using Student’s t-test. (G) Bar plot comparing the increase in the percent of mCherry+ cells following treatment of parental and G9a OE HUDEP-2 cells with either HU or aphidicolin (APH) as indicated (n=3). p-values were calculated using Student’s t-test. (H) Genome tracks for H3K9ac, H3K9me2, and H3K9me3 ChIP-seq signal in <t>K562</t> cells, data derived from previously published work . Highlighted regions denote globin gene clusters and the locus control region (LCR) as indicated. (I) EHMT2 (G9a) RNA transcript levels measured by qRT-PCR in parental K562 cells and K562 G9a OE cells as indicated. qRT-PCR signal is normalized to PPIB and RPLP0 . P-values were calculated using Student’s t-test (n=3). (J) HBG1/2 RNA transcript levels measured by qRT-PCR in parental K562 cells and G9a OE K562 cells with and without HU treatment. qRT-PCR signal is normalized to PPIB and RPLP0. P-values were calculated using Student’s t-test (n=3).
    K 562, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/custom%40ccl-243%4042473281
    Average 99 stars, based on 1 article reviews
    k-562 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human chronic myeloid leukemia cell line k562
    Results from <t>K562/luc</t> (expressing shNEG, Firefly luciferase, and GFP) alone (mono) or mixed with human primary bone marrow mesenchymal stem cells (with hMSC) were subcutaneously injected in mice to form xenografts. (A) Scheme demonstrating the experimental setup; samples were collected 21 days after subcutaneous injection of cells in mice. (B) Weight of xenografts formed by K562/luc mono or a mix with hMSCs in mice (n=5 in each variant), and the two-tailed, nonparametric Mann-Whitney test was used to check the difference significance; the exact significance ( P ) values are presented in the plot. (C-H) Short-read sequencing RNA analysis results of samples from cells isolated from xenografts mono and with hMSC treated for the last 14 days with vehicle (shNEG) by the fluorescence-activated cell sorting (FACS) with BD Aria. (C) Representative scatterplots (n=3) with the gating strategy used for the FACS-sorting of live xenograft cells (negative for Viability dye-eFluor780 staining), expressing GFP (GFP+) and stained positive with the antibody against human CD45 with BV421 fluorophore (hCD45+). (D-G) Results of differential expression analysis of the variant shNEG versus mono by DeSeq2 of RNA sequenced from FACS-sorted cells. Presented are the results from cells isolated from three different xenografts for each variant. (D) Principal component analysis. (E) Number of genes with fold change absolute value ≥ 50% and p-value corrected for multiple testing using the Benjamini-Hochberg P adj. ≤ 0.05, that are upregulated (UP) or downregulated (DOWN) in cells from xenograft (Xgraft) shNEG versus mono. (F) Expression level (counts corrected for the sample sequencing depth) in each xenograft (n=3) of the top 150 genes (each row) with the most significant (P adj. ) fold change in expression level. (G) The top of Gene Ontology Biological Processes (GOBP) terms from the Gene Set Enrichment Analysis (GSEA) of the DeSeq2 results, with the highest positive (left) and negative (right) normalized enrichment score (NES), P adj. ≤ 0.05 (FDR) and number of genes in the sample annotated per term (size) > 20. The running enrichment score is presented by a grey line for each of the ranked genes marked with a vertical black line. (H) The Reactome terms identified by the GSEA of the UP or DOWN genes in the variant shNEG versus mono, with NES ≥ 1.5 (absolute value), p value ≤ 0.05, and size > 30.
    Human Chronic Myeloid Leukemia Cell Line K562, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+k562+cells/K-562/bio_rxiv__64898__2026__05__29__728710-171-0-20
    Average 99 stars, based on 1 article reviews
    human chronic myeloid leukemia cell line k562 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    Image Search Results


    Circulating NK cell degranulation and angiogenic capabilities in T2DM patients with neuropathy and controls. Multicolor flow cytometry analysis for circulating NK cell degranulation activity against K562 target cells, showing the frequency of CD107 + circulating NK cells (A) Sample size n = 19–20. Data are shown as mean ± SEM, non‐parametric two‐sample Wilcoxon test, * p < 0.05. Representative dot plots and gating strategies used for the degranulation assay. Singlets were gated on SSC‐A/SSC‐H plot, followed by morphology identification of lymphocytes (SSC‐A/FSC‐A). NK cells were identified as CD3 − CD56 + cells, and CD107a + cells were gated to evaluate their degranulation capabilities. (B) HC: Nondiabetic controls; N: T2DM patients with neuropathy. Graphs of the average expression (2 −ΔCt ) of IFN‐γ (C), CD96 (D), and TIM3 (E) measured by real‐time Q‐PCR of sorted NK cells from N patients and nondiabetic controls. Sample size n = 6–7. EC tube network formation assay on Matrigel. HUVECs exposed to CM of FACS‐sorted NK from healthy control (CM NK‐HC) and T2DM patients with neuropathy (CM NK–N), for 16 h. Representative images (5× magnification) (F) and quantification of the number of segments (G), number of branches (H), total segments length (I), and total branches length (L). Sample size n = 3. Data are presented as mean ± SD, non‐parametric Student t test, * p < 0.05. Spheroid collagen invasion assay. Representative images (5× magnification) (M) of spheroid collagen invasion area on HUVECs exposed for 24 h to CM of FACS‐sorted NK from healthy control and T2DM patients with neuropathy measured as fold change vs. T0. Data are shown as the mean ± SD of 10 different spheroids for HC group and 12 different spheroids for the N group ( n = 10 and 12 biological replicates) (N). Non‐parametric Student t test (*** p < 0.001). The assays were performed on subsets of samples with sufficient PBMCs and sorted NK availability.

    Journal: The FASEB Journal

    Article Title: Circulating Natural Killer Cells in Patients With Type 2 Diabetes and Peripheral Neuropathy Are Altered in Their Frequency and Exhibit Impaired Functions and Angiogenic Activities

    doi: 10.1096/fj.202600263R

    Figure Lengend Snippet: Circulating NK cell degranulation and angiogenic capabilities in T2DM patients with neuropathy and controls. Multicolor flow cytometry analysis for circulating NK cell degranulation activity against K562 target cells, showing the frequency of CD107 + circulating NK cells (A) Sample size n = 19–20. Data are shown as mean ± SEM, non‐parametric two‐sample Wilcoxon test, * p < 0.05. Representative dot plots and gating strategies used for the degranulation assay. Singlets were gated on SSC‐A/SSC‐H plot, followed by morphology identification of lymphocytes (SSC‐A/FSC‐A). NK cells were identified as CD3 − CD56 + cells, and CD107a + cells were gated to evaluate their degranulation capabilities. (B) HC: Nondiabetic controls; N: T2DM patients with neuropathy. Graphs of the average expression (2 −ΔCt ) of IFN‐γ (C), CD96 (D), and TIM3 (E) measured by real‐time Q‐PCR of sorted NK cells from N patients and nondiabetic controls. Sample size n = 6–7. EC tube network formation assay on Matrigel. HUVECs exposed to CM of FACS‐sorted NK from healthy control (CM NK‐HC) and T2DM patients with neuropathy (CM NK–N), for 16 h. Representative images (5× magnification) (F) and quantification of the number of segments (G), number of branches (H), total segments length (I), and total branches length (L). Sample size n = 3. Data are presented as mean ± SD, non‐parametric Student t test, * p < 0.05. Spheroid collagen invasion assay. Representative images (5× magnification) (M) of spheroid collagen invasion area on HUVECs exposed for 24 h to CM of FACS‐sorted NK from healthy control and T2DM patients with neuropathy measured as fold change vs. T0. Data are shown as the mean ± SD of 10 different spheroids for HC group and 12 different spheroids for the N group ( n = 10 and 12 biological replicates) (N). Non‐parametric Student t test (*** p < 0.001). The assays were performed on subsets of samples with sufficient PBMCs and sorted NK availability.

    Article Snippet: The human erythroid K562 cells (ATCC) were cultured in RPMI 1640 medium (Euroclone) supplemented with 10% FBS (Euroclone), 2 mM L‐glutamine (Euroclone), 100 U/mL penicillin, and 100 μg/mL streptomycin (Euroclone) at 37°C in a 5% CO 2 atmosphere, and used for the NK cell degranulation assay as target cells.

    Techniques: Flow Cytometry, Analysis, Activity Assay, Degranulation Assay, Morphology, Expressing, Tube Network Formation Assay, Control, Invasion Assay, Spheroids

    (A) Representative immunoblot analysis of G9a, WIZ, BCL11A, H3K9me2 and H3K9me3 in HUDEP-2 whole cell extract, soluble, and chromatin-bound fractions from cells treated with vehicle (Veh), hydroxyurea (HU), or aphidicolin (APH) as indicated. Tubulin serves as a loading control for the soluble fraction and total H3 as a loading control for the chromatin-bound fraction, while Ser345-phosphorylated CHEK1 (p-Chk1) is a marker of DNA replication stress. (B–C) Quantification of immunoblot signals from (A) along with other replicates (n = 3, blots not shown) for (B) whole cell extract and (C) soluble and chromatin-bound fractions as indicated. Signal intensities are normalized to indicated loading controls. Statistical significance was determined via two-way ANOVA and p-values > 0.05 are indicated as ns (not significant). (D) Representative immunoblot of FLAG and G9a signal in parental HUDEP-2 cells, HUDEP-2 cells transduced with a FLAG-G9a overexpression construct containing a puromycin resistance gene prior to selection, and similarly transduced HUDEP-2 cells selected with puromycin for 72 hr (hereafter referred to as G9a OE cells). β-actin serves as a loading control. (E) Quantification of the representative immunoblot shown in (D). FLAG and G9a signal is normalized to their corresponding β-actin loading control. (F) EHMT2 (G9a) RNA transcript levels in parental HUDEP-2 cells and G9a OE HUDEP-2 cells (n=3). p-value was calculated using Student’s t-test. (G) Bar plot comparing the increase in the percent of mCherry+ cells following treatment of parental and G9a OE HUDEP-2 cells with either HU or aphidicolin (APH) as indicated (n=3). p-values were calculated using Student’s t-test. (H) Genome tracks for H3K9ac, H3K9me2, and H3K9me3 ChIP-seq signal in K562 cells, data derived from previously published work . Highlighted regions denote globin gene clusters and the locus control region (LCR) as indicated. (I) EHMT2 (G9a) RNA transcript levels measured by qRT-PCR in parental K562 cells and K562 G9a OE cells as indicated. qRT-PCR signal is normalized to PPIB and RPLP0 . P-values were calculated using Student’s t-test (n=3). (J) HBG1/2 RNA transcript levels measured by qRT-PCR in parental K562 cells and G9a OE K562 cells with and without HU treatment. qRT-PCR signal is normalized to PPIB and RPLP0. P-values were calculated using Student’s t-test (n=3).

    Journal: bioRxiv

    Article Title: DNA replication stress redistributes the histone methyltransferase G9a and activates lineage-specific gene expression

    doi: 10.64898/2026.10.06.757090

    Figure Lengend Snippet: (A) Representative immunoblot analysis of G9a, WIZ, BCL11A, H3K9me2 and H3K9me3 in HUDEP-2 whole cell extract, soluble, and chromatin-bound fractions from cells treated with vehicle (Veh), hydroxyurea (HU), or aphidicolin (APH) as indicated. Tubulin serves as a loading control for the soluble fraction and total H3 as a loading control for the chromatin-bound fraction, while Ser345-phosphorylated CHEK1 (p-Chk1) is a marker of DNA replication stress. (B–C) Quantification of immunoblot signals from (A) along with other replicates (n = 3, blots not shown) for (B) whole cell extract and (C) soluble and chromatin-bound fractions as indicated. Signal intensities are normalized to indicated loading controls. Statistical significance was determined via two-way ANOVA and p-values > 0.05 are indicated as ns (not significant). (D) Representative immunoblot of FLAG and G9a signal in parental HUDEP-2 cells, HUDEP-2 cells transduced with a FLAG-G9a overexpression construct containing a puromycin resistance gene prior to selection, and similarly transduced HUDEP-2 cells selected with puromycin for 72 hr (hereafter referred to as G9a OE cells). β-actin serves as a loading control. (E) Quantification of the representative immunoblot shown in (D). FLAG and G9a signal is normalized to their corresponding β-actin loading control. (F) EHMT2 (G9a) RNA transcript levels in parental HUDEP-2 cells and G9a OE HUDEP-2 cells (n=3). p-value was calculated using Student’s t-test. (G) Bar plot comparing the increase in the percent of mCherry+ cells following treatment of parental and G9a OE HUDEP-2 cells with either HU or aphidicolin (APH) as indicated (n=3). p-values were calculated using Student’s t-test. (H) Genome tracks for H3K9ac, H3K9me2, and H3K9me3 ChIP-seq signal in K562 cells, data derived from previously published work . Highlighted regions denote globin gene clusters and the locus control region (LCR) as indicated. (I) EHMT2 (G9a) RNA transcript levels measured by qRT-PCR in parental K562 cells and K562 G9a OE cells as indicated. qRT-PCR signal is normalized to PPIB and RPLP0 . P-values were calculated using Student’s t-test (n=3). (J) HBG1/2 RNA transcript levels measured by qRT-PCR in parental K562 cells and G9a OE K562 cells with and without HU treatment. qRT-PCR signal is normalized to PPIB and RPLP0. P-values were calculated using Student’s t-test (n=3).

    Article Snippet: K562 human chronic myelogenous leukemia cells (ATCC, CCL-243) were cultured in RPMI 1640 media (Corning, 15-040-CV) supplemented with 10% fetal bovine serum (Gibco, A52567-01) and 4mM L-glutamine (Cytiva, SH30034.01).

    Techniques: Western Blot, Analysis, Control, Marker, Transduction, Over Expression, Construct, Selection, ChIP-sequencing, Derivative Assay, Quantitative RT-PCR

    (A) Schematic of EdU labeling and compound treatment for a subset of assays shown in this figure. Cells were labeled with EdU under three conditions: Vehicle (Veh), with 4 hr vehicle treatment followed by 15 min EdU pulse, Hydroxyurea (HU), with 15 min EdU pulse followed by 4 hr hydroxyurea (HU) treatment at a dose that fully arrests fork progression, and Post replication DNA (post-rep DNA), with a 15 min EdU pulse followed by 4 hr thymidine chase. Timelines of treatment are shown (left) as well as position of EdU labeling indicated in green on replication forks (right). (B) Representative streptavidin-HRP immunoblots for EdU-labeled DNA pulled down by H3K9me2 or IgG click-CUT&RUN in HUDEP-2 cells treated with Veh or HU as described in (A). The indicated amount of DNA was loaded in each lane. Equal DNA loading was assessed using a pan DNA stain (SYBR-Gold). (C) Representative immunofluorescence images of foci per nucleus for G9a, WIZ, H3K9me2, or H3K9me3 in proximity to nascent DNA (labeled by EdU) using a proximity ligation assay (PLA). PLA signals (red) are shown for each condition described in (A) as indicated, and nuclei are counterstained with DAPI (blue). Cells in S phase, determined by the presence of EdU-labeled DNA, are represented by white dashed circles. Representative selection of EdU-positive and EdU-negative signal is shown in Figure S8A. (D) Quantification of PLA foci per nucleus for G9a, WIZ, H3K9me2, and H3K9me3 from the PLA shown in (C). Data are presented as box-and-whisker plots showing median and interquartile range. Statistical significance was calculated using a Wilcoxon test with Benjamini-Hochberg p-value correction (**p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant). The number of nuclei assessed for each condition is indicated. (E) Schematic of EdU labeling and dWIZ-2/HU treatment for subset of assays shown in this figure. Cells were labeled with EdU and treated with dWIZ-2 under two conditions: dWIZ-2 only, with 4 hr dWIZ-2 treatment followed by 15 min EdU pulse, and dWIZ-2 + HU, with 4 hr dWIZ-2 treatment followed by a 15 min EdU pulse followed by 4 hr HU. Timelines of treatment are shown with dWIZ-2 shown in blue (left) as well as position of EdU labeling indicated in green on replication forks (right). (F) Representative immunofluorescence images of PLA signals (red) for G9a or H3K9me2 in proximity to EdU for vehicle-treated, HU, post-rep DNA, dWIZ-2 only, and dWIZ-2 + HU conditions as described in (A) and (E). Nuclei are counterstained with DAPI (blue). Cells in S phase are represented by white dashed circles. (G) Quantification of PLA foci for G9a and H3K9me2 in proximity to EdU in cells treated with vehicle or HU with or without degradation of WIZ through dWIZ-2 pretreatment as shown in (E). Data are presented as box-and-whisker plots. Statistical significance was calculated using a Wilcoxon test with Benjamini-Hochberg p-value correction (**p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant). The number of nuclei assessed for each condition is indicated. (H) Representative immunoblot of 3% pulldown input (left) and proteins associated with nascent DNA identified by iPOND (isolation of proteins on nascent DNA) (right) in K562 cells treated with vehicle or HU, or following a post-replicative chase (see (A)). In iPOND, EdU incorporated into nascent DNA is conjugated to biotin azide by click chemistry , enabling affinity purification of nascent DNA and associated proteins. The (-) azide sample, in which biotin azide was omitted from the click reaction, serves as a negative control for nonspecific protein recovery during purification. (I) Quantification of H3K9me2 iPOND signal from (H), normalized to H3 iPOND signal and the input H3K9me2/H3 ratio, at vehicle and HU-treated nascent DNA and at post-replication DNA (n=3). (J) Representative immunoblot of 3% pulldown input (left) and iPOND fractions (right) from Veh, HU, post-rep DNA, dWIZ-2 only, and dWIZ-2 + HU (see (A) and (E)) from K562 cells. (K) Quantification of H3K9me2 iPOND signal from (J), normalized to H3 iPOND signal and the input H3K9me2/H3 ratio.

    Journal: bioRxiv

    Article Title: DNA replication stress redistributes the histone methyltransferase G9a and activates lineage-specific gene expression

    doi: 10.64898/2026.10.06.757090

    Figure Lengend Snippet: (A) Schematic of EdU labeling and compound treatment for a subset of assays shown in this figure. Cells were labeled with EdU under three conditions: Vehicle (Veh), with 4 hr vehicle treatment followed by 15 min EdU pulse, Hydroxyurea (HU), with 15 min EdU pulse followed by 4 hr hydroxyurea (HU) treatment at a dose that fully arrests fork progression, and Post replication DNA (post-rep DNA), with a 15 min EdU pulse followed by 4 hr thymidine chase. Timelines of treatment are shown (left) as well as position of EdU labeling indicated in green on replication forks (right). (B) Representative streptavidin-HRP immunoblots for EdU-labeled DNA pulled down by H3K9me2 or IgG click-CUT&RUN in HUDEP-2 cells treated with Veh or HU as described in (A). The indicated amount of DNA was loaded in each lane. Equal DNA loading was assessed using a pan DNA stain (SYBR-Gold). (C) Representative immunofluorescence images of foci per nucleus for G9a, WIZ, H3K9me2, or H3K9me3 in proximity to nascent DNA (labeled by EdU) using a proximity ligation assay (PLA). PLA signals (red) are shown for each condition described in (A) as indicated, and nuclei are counterstained with DAPI (blue). Cells in S phase, determined by the presence of EdU-labeled DNA, are represented by white dashed circles. Representative selection of EdU-positive and EdU-negative signal is shown in Figure S8A. (D) Quantification of PLA foci per nucleus for G9a, WIZ, H3K9me2, and H3K9me3 from the PLA shown in (C). Data are presented as box-and-whisker plots showing median and interquartile range. Statistical significance was calculated using a Wilcoxon test with Benjamini-Hochberg p-value correction (**p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant). The number of nuclei assessed for each condition is indicated. (E) Schematic of EdU labeling and dWIZ-2/HU treatment for subset of assays shown in this figure. Cells were labeled with EdU and treated with dWIZ-2 under two conditions: dWIZ-2 only, with 4 hr dWIZ-2 treatment followed by 15 min EdU pulse, and dWIZ-2 + HU, with 4 hr dWIZ-2 treatment followed by a 15 min EdU pulse followed by 4 hr HU. Timelines of treatment are shown with dWIZ-2 shown in blue (left) as well as position of EdU labeling indicated in green on replication forks (right). (F) Representative immunofluorescence images of PLA signals (red) for G9a or H3K9me2 in proximity to EdU for vehicle-treated, HU, post-rep DNA, dWIZ-2 only, and dWIZ-2 + HU conditions as described in (A) and (E). Nuclei are counterstained with DAPI (blue). Cells in S phase are represented by white dashed circles. (G) Quantification of PLA foci for G9a and H3K9me2 in proximity to EdU in cells treated with vehicle or HU with or without degradation of WIZ through dWIZ-2 pretreatment as shown in (E). Data are presented as box-and-whisker plots. Statistical significance was calculated using a Wilcoxon test with Benjamini-Hochberg p-value correction (**p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant). The number of nuclei assessed for each condition is indicated. (H) Representative immunoblot of 3% pulldown input (left) and proteins associated with nascent DNA identified by iPOND (isolation of proteins on nascent DNA) (right) in K562 cells treated with vehicle or HU, or following a post-replicative chase (see (A)). In iPOND, EdU incorporated into nascent DNA is conjugated to biotin azide by click chemistry , enabling affinity purification of nascent DNA and associated proteins. The (-) azide sample, in which biotin azide was omitted from the click reaction, serves as a negative control for nonspecific protein recovery during purification. (I) Quantification of H3K9me2 iPOND signal from (H), normalized to H3 iPOND signal and the input H3K9me2/H3 ratio, at vehicle and HU-treated nascent DNA and at post-replication DNA (n=3). (J) Representative immunoblot of 3% pulldown input (left) and iPOND fractions (right) from Veh, HU, post-rep DNA, dWIZ-2 only, and dWIZ-2 + HU (see (A) and (E)) from K562 cells. (K) Quantification of H3K9me2 iPOND signal from (J), normalized to H3 iPOND signal and the input H3K9me2/H3 ratio.

    Article Snippet: K562 human chronic myelogenous leukemia cells (ATCC, CCL-243) were cultured in RPMI 1640 media (Corning, 15-040-CV) supplemented with 10% fetal bovine serum (Gibco, A52567-01) and 4mM L-glutamine (Cytiva, SH30034.01).

    Techniques: Labeling, Western Blot, Staining, Immunofluorescence, Proximity Ligation Assay, Selection, Whisker Assay, Isolation, Affinity Purification, Negative Control, Purification

    Results from K562/luc (expressing shNEG, Firefly luciferase, and GFP) alone (mono) or mixed with human primary bone marrow mesenchymal stem cells (with hMSC) were subcutaneously injected in mice to form xenografts. (A) Scheme demonstrating the experimental setup; samples were collected 21 days after subcutaneous injection of cells in mice. (B) Weight of xenografts formed by K562/luc mono or a mix with hMSCs in mice (n=5 in each variant), and the two-tailed, nonparametric Mann-Whitney test was used to check the difference significance; the exact significance ( P ) values are presented in the plot. (C-H) Short-read sequencing RNA analysis results of samples from cells isolated from xenografts mono and with hMSC treated for the last 14 days with vehicle (shNEG) by the fluorescence-activated cell sorting (FACS) with BD Aria. (C) Representative scatterplots (n=3) with the gating strategy used for the FACS-sorting of live xenograft cells (negative for Viability dye-eFluor780 staining), expressing GFP (GFP+) and stained positive with the antibody against human CD45 with BV421 fluorophore (hCD45+). (D-G) Results of differential expression analysis of the variant shNEG versus mono by DeSeq2 of RNA sequenced from FACS-sorted cells. Presented are the results from cells isolated from three different xenografts for each variant. (D) Principal component analysis. (E) Number of genes with fold change absolute value ≥ 50% and p-value corrected for multiple testing using the Benjamini-Hochberg P adj. ≤ 0.05, that are upregulated (UP) or downregulated (DOWN) in cells from xenograft (Xgraft) shNEG versus mono. (F) Expression level (counts corrected for the sample sequencing depth) in each xenograft (n=3) of the top 150 genes (each row) with the most significant (P adj. ) fold change in expression level. (G) The top of Gene Ontology Biological Processes (GOBP) terms from the Gene Set Enrichment Analysis (GSEA) of the DeSeq2 results, with the highest positive (left) and negative (right) normalized enrichment score (NES), P adj. ≤ 0.05 (FDR) and number of genes in the sample annotated per term (size) > 20. The running enrichment score is presented by a grey line for each of the ranked genes marked with a vertical black line. (H) The Reactome terms identified by the GSEA of the UP or DOWN genes in the variant shNEG versus mono, with NES ≥ 1.5 (absolute value), p value ≤ 0.05, and size > 30.

    Journal: bioRxiv

    Article Title: TIAR-dependent coordination of alternative splicing and lipid peroxidation is required for CML cell resistance to imatinib in the bone marrow stroma

    doi: 10.64898/2026.05.29.728710

    Figure Lengend Snippet: Results from K562/luc (expressing shNEG, Firefly luciferase, and GFP) alone (mono) or mixed with human primary bone marrow mesenchymal stem cells (with hMSC) were subcutaneously injected in mice to form xenografts. (A) Scheme demonstrating the experimental setup; samples were collected 21 days after subcutaneous injection of cells in mice. (B) Weight of xenografts formed by K562/luc mono or a mix with hMSCs in mice (n=5 in each variant), and the two-tailed, nonparametric Mann-Whitney test was used to check the difference significance; the exact significance ( P ) values are presented in the plot. (C-H) Short-read sequencing RNA analysis results of samples from cells isolated from xenografts mono and with hMSC treated for the last 14 days with vehicle (shNEG) by the fluorescence-activated cell sorting (FACS) with BD Aria. (C) Representative scatterplots (n=3) with the gating strategy used for the FACS-sorting of live xenograft cells (negative for Viability dye-eFluor780 staining), expressing GFP (GFP+) and stained positive with the antibody against human CD45 with BV421 fluorophore (hCD45+). (D-G) Results of differential expression analysis of the variant shNEG versus mono by DeSeq2 of RNA sequenced from FACS-sorted cells. Presented are the results from cells isolated from three different xenografts for each variant. (D) Principal component analysis. (E) Number of genes with fold change absolute value ≥ 50% and p-value corrected for multiple testing using the Benjamini-Hochberg P adj. ≤ 0.05, that are upregulated (UP) or downregulated (DOWN) in cells from xenograft (Xgraft) shNEG versus mono. (F) Expression level (counts corrected for the sample sequencing depth) in each xenograft (n=3) of the top 150 genes (each row) with the most significant (P adj. ) fold change in expression level. (G) The top of Gene Ontology Biological Processes (GOBP) terms from the Gene Set Enrichment Analysis (GSEA) of the DeSeq2 results, with the highest positive (left) and negative (right) normalized enrichment score (NES), P adj. ≤ 0.05 (FDR) and number of genes in the sample annotated per term (size) > 20. The running enrichment score is presented by a grey line for each of the ranked genes marked with a vertical black line. (H) The Reactome terms identified by the GSEA of the UP or DOWN genes in the variant shNEG versus mono, with NES ≥ 1.5 (absolute value), p value ≤ 0.05, and size > 30.

    Article Snippet: Human chronic myeloid leukemia cell line K562 (#CCL-243) and bone marrow stroma fibroblast cell line HS-5 (#CRL-11882) were obtained from American Type Culture Collection (USA); human chronic myeloid leukemia cell line LAMA-84 (#ACC 168) was from DSMZ.

    Techniques: Expressing, Luciferase, Injection, Variant Assay, Two Tailed Test, MANN-WHITNEY, Sequencing, Isolation, Fluorescence, FACS, Staining, Quantitative Proteomics

    (A) Scheme explaining experimental steps of xenograft formation by K562/luc (expressing shNEG, Firefly luciferase, and GFP) mixed with human primary bone marrow mesenchymal stem cells (hMSC) subcutaneously injected in mice 7 days before initiation of treatment with IM for the following 14 days, when the GFP and human CD45 positive cells were FACS-sorted from xenografts for RNA isolation and sequencing. (B) Number of intersecting genes (compared groups indicated by black dot) that at the RNA level are upregulated (UP; log2 value of fold change ≥ 0.6) or downregulated (DOWN; log2 value of fold change ≤ -0.6) in shNEG cells xenografts imatinib versus vehicle treated and in CD34 positive cells from bone marrow biopsies of a patient with CML (data deposited at GEO under accession number GSE310243; from ) obtained after 6 months of imatinib therapy (combined samples SRR36072325 and SRR36072321) versus obtained at the diagnosis (combined SRR36072320 and SRR36072324). (B-D) Yellow shadow marks a group of genes that are UP or DOWN upon imatinib treatment in shNEG and CML cells (shNEG&CML), selected for subsequent analysis in (C) and (D). (C) Reactome terms identified by the GSEA analysis of the UP or DOWN genes in shNEG&CML with normalized enrichment score ≥ 1.5 (absolute value), p value ≤ 0.05, and number of genes in the sample annotated per term (size) ≥ 15. (C-D) The Reactome leading-edge genes identified by GSEA, annotated to terms marked with a brown triangle in (C) were selected to compare their expression level in single-cell RNA-seq data in (D) from bone marrow biopsies of healthy donors and CML patients with different responses to imatinib therapy. (D) Analysis of data at the Single-cell atlas of diagnostic Chronic Myeloid Leukemia bone marrow (scdbm) for CD34+ cells subtype . Data and detailed description of patient classification available: http://scdbm.ddnetbio.com ; A – responded to IM within 12 months; B – IM treatment failed within 18 months; C – resistant to IM and other TKI-s.

    Journal: bioRxiv

    Article Title: TIAR-dependent coordination of alternative splicing and lipid peroxidation is required for CML cell resistance to imatinib in the bone marrow stroma

    doi: 10.64898/2026.05.29.728710

    Figure Lengend Snippet: (A) Scheme explaining experimental steps of xenograft formation by K562/luc (expressing shNEG, Firefly luciferase, and GFP) mixed with human primary bone marrow mesenchymal stem cells (hMSC) subcutaneously injected in mice 7 days before initiation of treatment with IM for the following 14 days, when the GFP and human CD45 positive cells were FACS-sorted from xenografts for RNA isolation and sequencing. (B) Number of intersecting genes (compared groups indicated by black dot) that at the RNA level are upregulated (UP; log2 value of fold change ≥ 0.6) or downregulated (DOWN; log2 value of fold change ≤ -0.6) in shNEG cells xenografts imatinib versus vehicle treated and in CD34 positive cells from bone marrow biopsies of a patient with CML (data deposited at GEO under accession number GSE310243; from ) obtained after 6 months of imatinib therapy (combined samples SRR36072325 and SRR36072321) versus obtained at the diagnosis (combined SRR36072320 and SRR36072324). (B-D) Yellow shadow marks a group of genes that are UP or DOWN upon imatinib treatment in shNEG and CML cells (shNEG&CML), selected for subsequent analysis in (C) and (D). (C) Reactome terms identified by the GSEA analysis of the UP or DOWN genes in shNEG&CML with normalized enrichment score ≥ 1.5 (absolute value), p value ≤ 0.05, and number of genes in the sample annotated per term (size) ≥ 15. (C-D) The Reactome leading-edge genes identified by GSEA, annotated to terms marked with a brown triangle in (C) were selected to compare their expression level in single-cell RNA-seq data in (D) from bone marrow biopsies of healthy donors and CML patients with different responses to imatinib therapy. (D) Analysis of data at the Single-cell atlas of diagnostic Chronic Myeloid Leukemia bone marrow (scdbm) for CD34+ cells subtype . Data and detailed description of patient classification available: http://scdbm.ddnetbio.com ; A – responded to IM within 12 months; B – IM treatment failed within 18 months; C – resistant to IM and other TKI-s.

    Article Snippet: Human chronic myeloid leukemia cell line K562 (#CCL-243) and bone marrow stroma fibroblast cell line HS-5 (#CRL-11882) were obtained from American Type Culture Collection (USA); human chronic myeloid leukemia cell line LAMA-84 (#ACC 168) was from DSMZ.

    Techniques: Expressing, Luciferase, Injection, Isolation, Sequencing, Biomarker Discovery, Single Cell, RNA Sequencing, Diagnostic Assay

    (A) Colony formation by K562 cells expressing shRNA non-targeting (shNEG) or targeting mRNA of TIAL1 (shTIAR), TIA1 (shTIA-1), or FMR1 (shFMRP) that were collected from ex vivo hypoxic (1.5% O2) co-culture with HS-5 bone marrow stromal fibroblasts and treated with 1 μM imatinib (IM) or 50nM Talazoparib (BMN) added in two doses following the experimental scheme (left panel). Number of colonies in each of the 3 technical replicates from 3-4 independent biological experiments presented as % change relative to the untreated cells (dashed black line) set as 100 %. Student’s two-tailed t-test was used to compare two samples marked by the black line; #### or **** - p<0.0001, ns - p > 0.05. (B) Scheme explaining the experimental setup based on the subcutaneous implantation in mice of 3D printed scaffolds (photo taken with a Samsung mobile phone camera) seeded with human cells differentiated into osteoblasts and K562/luc cells with shNEG, shTIAR or shTIA-1, followed by IM treatment for 14 days. (C) Bioluminescence signal monitored in mice after 2 weeks of IM or vehicle treatment (timeline explained in (B) ) following luciferin injection, collected in the Burker’s Xtreme In-Vivo chamber for 30 sec, and overlaid on the mouse X-ray image. Scale presents the signal intensity of the color coding. (D) Sum of the signal intensity (P) collected per second (s) and area (mm 2 ) for each mouse analyzed (single dot) is presented. (E) Scheme explaining experimental steps of xenograft formation by K562/luc (expressing shNEG or shTIAR, Firefly luciferase, and GFP) mixed with human primary bone marrow mesenchymal stem cells (hMSC) subcutaneously injected in mice 7 days before initiation of treatment with IM for the following 14 days. (F) Weight of each xenograft isolated from mice (single dot) formed by K562/luc cells with shNEG or shTIAR (as in (E) ) presented as fold change of the weight mean value of xenografts from mice treated with vehicle; mean value indicated with the black line. The nonparametric two-tailed Mann-Whitney test was used for comparisons indicated by black lines underneath the exact significance ( P ) values are presented in the plot. (A,D,F) Two-way Anova was used to compare shTIAR upon IM versus other variants; @ - P < 0.002.

    Journal: bioRxiv

    Article Title: TIAR-dependent coordination of alternative splicing and lipid peroxidation is required for CML cell resistance to imatinib in the bone marrow stroma

    doi: 10.64898/2026.05.29.728710

    Figure Lengend Snippet: (A) Colony formation by K562 cells expressing shRNA non-targeting (shNEG) or targeting mRNA of TIAL1 (shTIAR), TIA1 (shTIA-1), or FMR1 (shFMRP) that were collected from ex vivo hypoxic (1.5% O2) co-culture with HS-5 bone marrow stromal fibroblasts and treated with 1 μM imatinib (IM) or 50nM Talazoparib (BMN) added in two doses following the experimental scheme (left panel). Number of colonies in each of the 3 technical replicates from 3-4 independent biological experiments presented as % change relative to the untreated cells (dashed black line) set as 100 %. Student’s two-tailed t-test was used to compare two samples marked by the black line; #### or **** - p<0.0001, ns - p > 0.05. (B) Scheme explaining the experimental setup based on the subcutaneous implantation in mice of 3D printed scaffolds (photo taken with a Samsung mobile phone camera) seeded with human cells differentiated into osteoblasts and K562/luc cells with shNEG, shTIAR or shTIA-1, followed by IM treatment for 14 days. (C) Bioluminescence signal monitored in mice after 2 weeks of IM or vehicle treatment (timeline explained in (B) ) following luciferin injection, collected in the Burker’s Xtreme In-Vivo chamber for 30 sec, and overlaid on the mouse X-ray image. Scale presents the signal intensity of the color coding. (D) Sum of the signal intensity (P) collected per second (s) and area (mm 2 ) for each mouse analyzed (single dot) is presented. (E) Scheme explaining experimental steps of xenograft formation by K562/luc (expressing shNEG or shTIAR, Firefly luciferase, and GFP) mixed with human primary bone marrow mesenchymal stem cells (hMSC) subcutaneously injected in mice 7 days before initiation of treatment with IM for the following 14 days. (F) Weight of each xenograft isolated from mice (single dot) formed by K562/luc cells with shNEG or shTIAR (as in (E) ) presented as fold change of the weight mean value of xenografts from mice treated with vehicle; mean value indicated with the black line. The nonparametric two-tailed Mann-Whitney test was used for comparisons indicated by black lines underneath the exact significance ( P ) values are presented in the plot. (A,D,F) Two-way Anova was used to compare shTIAR upon IM versus other variants; @ - P < 0.002.

    Article Snippet: Human chronic myeloid leukemia cell line K562 (#CCL-243) and bone marrow stroma fibroblast cell line HS-5 (#CRL-11882) were obtained from American Type Culture Collection (USA); human chronic myeloid leukemia cell line LAMA-84 (#ACC 168) was from DSMZ.

    Techniques: Expressing, shRNA, Ex Vivo, Co-Culture Assay, Two Tailed Test, Injection, In Vivo, Luciferase, Isolation, MANN-WHITNEY

    (A) Comparison of gene expression in K562/luc cells with shNEG or shTIAR, FACS-sorted from xenografts (Xgraft), with level upon 2 weeks of IM versus vehicle (C) treatment changed with log2 value of fold change (Log2FC) ≥ 0.6 (UP) or ≤ -0.6 (DOWN); reversed regulation in shTIAR cells in purple. (B) Gene Ontology Molecular Function terms identified by the GSEA of genes that upon IM vs C in Xgraft of shNEG are reversely regulated in shTIAR (shaded in purple). In grey circles - UP (Log2FC > 0.6) n = 1993, brown circles DOWN (Log2FC < -0.6) n = 1756. Selected terms with NESabs ≥ 1.45, p-value ≤ 0.05, and the number of genes in the sample annotated per term (size) ≥ 10; n -number of genes. (C) Proportion of alternative splicing events (AS) changed upon shTIAR versus shNEG in cells from xenografts treated with vehicle (C) or imatinib (IM) for 2 weeks. Significant events from rMATS analysis requiring at least 20 reads/event, absolute change in PSI (Percent Spliced In) > 0.1 with FDR ≤ 0.05; total number in 3 experiments (n) above the bar. (D) Comparison of intron retention (RI; left panel) and cassette exon (CE; right panel) AS with significant PSI changed in shTIAR versus shNEG in cells from Xgraft or CO treated with IM. (E) Change in expression level of genes in Xgraft IM versus vehicle-treated for a subset of genes with significant changes shTIAR vs shNEG in RI (left panel) or SE (right panel) in cells from Xgraft and CO treated with IM; Log2FC ≤ -0.6 in brown, ≥ 0.6 in grey. (F) Difference in PSI value of CE, RI, and mutually exclusive exons (MXE) AS in: moro – shTIAR versus shNEG xenograft cells from mice treated with IM (Xgraft_IM); yellow – CD34 + enriched cells from bone marrow biopsies of a CML patient collected at 6-month IM therapy versus diagnosis GSE310243 (see in ). Included only with PSI > 0.1 and with FDR ≤ 0.05. (G) Expression level of genes with changes in AS (selected in (E) and (F) ) analyzed at the scdbm for the CD34 + cells subtype. Patient classification in .

    Journal: bioRxiv

    Article Title: TIAR-dependent coordination of alternative splicing and lipid peroxidation is required for CML cell resistance to imatinib in the bone marrow stroma

    doi: 10.64898/2026.05.29.728710

    Figure Lengend Snippet: (A) Comparison of gene expression in K562/luc cells with shNEG or shTIAR, FACS-sorted from xenografts (Xgraft), with level upon 2 weeks of IM versus vehicle (C) treatment changed with log2 value of fold change (Log2FC) ≥ 0.6 (UP) or ≤ -0.6 (DOWN); reversed regulation in shTIAR cells in purple. (B) Gene Ontology Molecular Function terms identified by the GSEA of genes that upon IM vs C in Xgraft of shNEG are reversely regulated in shTIAR (shaded in purple). In grey circles - UP (Log2FC > 0.6) n = 1993, brown circles DOWN (Log2FC < -0.6) n = 1756. Selected terms with NESabs ≥ 1.45, p-value ≤ 0.05, and the number of genes in the sample annotated per term (size) ≥ 10; n -number of genes. (C) Proportion of alternative splicing events (AS) changed upon shTIAR versus shNEG in cells from xenografts treated with vehicle (C) or imatinib (IM) for 2 weeks. Significant events from rMATS analysis requiring at least 20 reads/event, absolute change in PSI (Percent Spliced In) > 0.1 with FDR ≤ 0.05; total number in 3 experiments (n) above the bar. (D) Comparison of intron retention (RI; left panel) and cassette exon (CE; right panel) AS with significant PSI changed in shTIAR versus shNEG in cells from Xgraft or CO treated with IM. (E) Change in expression level of genes in Xgraft IM versus vehicle-treated for a subset of genes with significant changes shTIAR vs shNEG in RI (left panel) or SE (right panel) in cells from Xgraft and CO treated with IM; Log2FC ≤ -0.6 in brown, ≥ 0.6 in grey. (F) Difference in PSI value of CE, RI, and mutually exclusive exons (MXE) AS in: moro – shTIAR versus shNEG xenograft cells from mice treated with IM (Xgraft_IM); yellow – CD34 + enriched cells from bone marrow biopsies of a CML patient collected at 6-month IM therapy versus diagnosis GSE310243 (see in ). Included only with PSI > 0.1 and with FDR ≤ 0.05. (G) Expression level of genes with changes in AS (selected in (E) and (F) ) analyzed at the scdbm for the CD34 + cells subtype. Patient classification in .

    Article Snippet: Human chronic myeloid leukemia cell line K562 (#CCL-243) and bone marrow stroma fibroblast cell line HS-5 (#CRL-11882) were obtained from American Type Culture Collection (USA); human chronic myeloid leukemia cell line LAMA-84 (#ACC 168) was from DSMZ.

    Techniques: Comparison, Gene Expression, Alternative Splicing, Expressing, Biomarker Discovery

    (A) Scheme explaining experimental setup to determine proteomic changes using the quantitative BONCAT (QuaNCAT). K562 cells expressing shNEG or shTIAR growing in co-culture with HS-5 cells under hypoxia (1.5% O2) for 1.5 days were treated with imatinib (IM) for 18h before the bioorthogonal noncanonical amino acid tagging (BONCAT) of nascent proteins synthesized in cells for 4h. (B) Upper panel - number of genes and nascent proteins showing increased (UP; log₂ fold change [Log₂FC] ≥ 0.6) or decreased (DOWN; Log₂FC ≤ −0.6) abundance in IM-treated shTIAR cells compared with shNEG cells, with a significance threshold of p ≤ 0.05. In total, 2186 nascent proteins were quantified in the BONCAT experiment. Lower panel - scatter plot showing intensity-based absolute quantification (iBAQ), used as an estimate of relative protein molar abundance, plotted against Log₂FC values for BONCAT-identified proteins in shTIAR versus shNEG cells. Purple dots indicate hits with significant changes at both the protein and mRNA levels. Dashed vertical lines mark the Log₂FC thresholds of −0.6 and 0.6. (C) Functional annotation Gene Ontology Molecular Function enrichment analysis of UP (brown) or DOWN (purple) proteins with ClueGO/CytoScape, displaying proteins annotated with the term; only one side enriched terms with FDR < 0.05. (D) Lower panel - number of proteins that upon shTIAR are UP and DOWN regulated, for which mRNA was detected in the RNA immunoprecipitated (IP) in TIAR protein complexes (RIP), enriched in samples obtained with anti-TIAR antibody versus the same isotype non-binding antibody (ISO) (n=3647). Upper panel - example Image of Western blotting analysis of IP, with a sample of cell lysate used for IP loaded for reference (input). (E) Changes in the mRNA level, determined by real-time PCR and quantified using the ddCT method, expressed as log2 of change between IM-treated versus untreated cells, detected in samples from whole cells (upper panel) and anti-TIAR RIP (lower panel). Mean of 3 independent experiments with ± range is presented. Student’s t-test two-way was used to compare the difference between IM to C; * p ≤ 0.05, ** p≤0.005. (F) Number of genes identified in anti-TIAR RIP that show significant changes in intron retention (RI) or cassette exon alternative splicing (CE) in shTIAR versus shNEG alternative splicing analysis of RNA from IM-treated cells. Number of genes in the intersection provided above the bar; comparisons indicated by the black dot. (G) Sashimi plot (middle panel) demonstrating splicing of EIF4A2 mRNA within the region encompassing exons 8-11 and 3’UTR in RNA from anti-TIAR RIP. Alternative splice site usage marked by the purple line, and the percent usage ± ME (n=3) in numbers by the lines, reads coverage from 0-145 shown in grey, alternatively spliced exon marked by shaded yellow. Gene region scheme in the top. (H) Percent transcripts with TIAR-dependent alternative exon inclusion in K562 cells from xenografts treated with IM. Student’s t-test was used to compare results from three experiments (each dot) for the mean value marked with a thick black line; * p = 0.021.

    Journal: bioRxiv

    Article Title: TIAR-dependent coordination of alternative splicing and lipid peroxidation is required for CML cell resistance to imatinib in the bone marrow stroma

    doi: 10.64898/2026.05.29.728710

    Figure Lengend Snippet: (A) Scheme explaining experimental setup to determine proteomic changes using the quantitative BONCAT (QuaNCAT). K562 cells expressing shNEG or shTIAR growing in co-culture with HS-5 cells under hypoxia (1.5% O2) for 1.5 days were treated with imatinib (IM) for 18h before the bioorthogonal noncanonical amino acid tagging (BONCAT) of nascent proteins synthesized in cells for 4h. (B) Upper panel - number of genes and nascent proteins showing increased (UP; log₂ fold change [Log₂FC] ≥ 0.6) or decreased (DOWN; Log₂FC ≤ −0.6) abundance in IM-treated shTIAR cells compared with shNEG cells, with a significance threshold of p ≤ 0.05. In total, 2186 nascent proteins were quantified in the BONCAT experiment. Lower panel - scatter plot showing intensity-based absolute quantification (iBAQ), used as an estimate of relative protein molar abundance, plotted against Log₂FC values for BONCAT-identified proteins in shTIAR versus shNEG cells. Purple dots indicate hits with significant changes at both the protein and mRNA levels. Dashed vertical lines mark the Log₂FC thresholds of −0.6 and 0.6. (C) Functional annotation Gene Ontology Molecular Function enrichment analysis of UP (brown) or DOWN (purple) proteins with ClueGO/CytoScape, displaying proteins annotated with the term; only one side enriched terms with FDR < 0.05. (D) Lower panel - number of proteins that upon shTIAR are UP and DOWN regulated, for which mRNA was detected in the RNA immunoprecipitated (IP) in TIAR protein complexes (RIP), enriched in samples obtained with anti-TIAR antibody versus the same isotype non-binding antibody (ISO) (n=3647). Upper panel - example Image of Western blotting analysis of IP, with a sample of cell lysate used for IP loaded for reference (input). (E) Changes in the mRNA level, determined by real-time PCR and quantified using the ddCT method, expressed as log2 of change between IM-treated versus untreated cells, detected in samples from whole cells (upper panel) and anti-TIAR RIP (lower panel). Mean of 3 independent experiments with ± range is presented. Student’s t-test two-way was used to compare the difference between IM to C; * p ≤ 0.05, ** p≤0.005. (F) Number of genes identified in anti-TIAR RIP that show significant changes in intron retention (RI) or cassette exon alternative splicing (CE) in shTIAR versus shNEG alternative splicing analysis of RNA from IM-treated cells. Number of genes in the intersection provided above the bar; comparisons indicated by the black dot. (G) Sashimi plot (middle panel) demonstrating splicing of EIF4A2 mRNA within the region encompassing exons 8-11 and 3’UTR in RNA from anti-TIAR RIP. Alternative splice site usage marked by the purple line, and the percent usage ± ME (n=3) in numbers by the lines, reads coverage from 0-145 shown in grey, alternatively spliced exon marked by shaded yellow. Gene region scheme in the top. (H) Percent transcripts with TIAR-dependent alternative exon inclusion in K562 cells from xenografts treated with IM. Student’s t-test was used to compare results from three experiments (each dot) for the mean value marked with a thick black line; * p = 0.021.

    Article Snippet: Human chronic myeloid leukemia cell line K562 (#CCL-243) and bone marrow stroma fibroblast cell line HS-5 (#CRL-11882) were obtained from American Type Culture Collection (USA); human chronic myeloid leukemia cell line LAMA-84 (#ACC 168) was from DSMZ.

    Techniques: Expressing, Co-Culture Assay, Synthesized, Quantitative Proteomics, Functional Assay, Immunoprecipitation, Binding Assay, Western Blot, Real-time Polymerase Chain Reaction, Alternative Splicing

    (A) Expression level of genes analyzed at the scdbm for CD34 + cells subtype; patient classification explained in . (B-H) Impact of shTIAR compared to shNEG analyzed in K562 cells that were co-cultured with HS-5 cells under hypoxia (1.5%O2) 2 days before initiation of 18h culture with imatinib (IM) treatment or without (C). (B) Protein level in whole cell extracts analyzed by Western blot, representative images of immunoblots (n=3) presented. (C) Mitochondrial (mit.) membrane potential measured using JC-1 probe; values for signal from probe aggregates (red) in polarized mitochondria expressed as % of signal from the probe in the cells (n=3), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP) used as a control. (C,D,F,H) Bars represent the mean of values from independent experiments (indicated by dots) with ± SD. Student’s t-test was used to determine the significance of the difference shTIAR vs shNEG (#) and IM vs C (*); * - p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, **** p ≤ 0.001 (D) Lipid peroxidation measured with click-it chemistry by flow cytometry. Fluorescence intensity GeoMean expressed as fold change of value in the untreated shNEG cells (n=5). (E-H) Presentation on the cluster of cell differentiation (CD) surface protein markers CD45 and CD235a on K562 cells with shNEG or shTIAR isolated from co-culture established in hypoxia (1.5%O2) a day before initiation of treatment with IM for 48h (E-G) or FACS-sorted K562/luc GFP positive cells from xenografts (H) . (E-F,H) Percentage of parental live cell subpopulations that are: double positive for CD45 and CD235a (CD235a&CD45), positive only for CD45, or only for CD235a, or negative for both CD markers. Representative scatter plots in (E) , summary of independent co-culture experiments (n=4) in (F) . (G) Fluorescence intensity of surface CD36 protein staining in the fraction of cells positive for CD235a or CD45. Numbers correspond to fold change in shTIAR to shNEG ± ME (n=2). (H) Percent GFP and hCD45-positive cells from different xenografts (n=4) that are positive for CD235a. Two-way ANOVA test was used to for comparison of shNEG_C to other variants (@), and p=0.0046.

    Journal: bioRxiv

    Article Title: TIAR-dependent coordination of alternative splicing and lipid peroxidation is required for CML cell resistance to imatinib in the bone marrow stroma

    doi: 10.64898/2026.05.29.728710

    Figure Lengend Snippet: (A) Expression level of genes analyzed at the scdbm for CD34 + cells subtype; patient classification explained in . (B-H) Impact of shTIAR compared to shNEG analyzed in K562 cells that were co-cultured with HS-5 cells under hypoxia (1.5%O2) 2 days before initiation of 18h culture with imatinib (IM) treatment or without (C). (B) Protein level in whole cell extracts analyzed by Western blot, representative images of immunoblots (n=3) presented. (C) Mitochondrial (mit.) membrane potential measured using JC-1 probe; values for signal from probe aggregates (red) in polarized mitochondria expressed as % of signal from the probe in the cells (n=3), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP) used as a control. (C,D,F,H) Bars represent the mean of values from independent experiments (indicated by dots) with ± SD. Student’s t-test was used to determine the significance of the difference shTIAR vs shNEG (#) and IM vs C (*); * - p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, **** p ≤ 0.001 (D) Lipid peroxidation measured with click-it chemistry by flow cytometry. Fluorescence intensity GeoMean expressed as fold change of value in the untreated shNEG cells (n=5). (E-H) Presentation on the cluster of cell differentiation (CD) surface protein markers CD45 and CD235a on K562 cells with shNEG or shTIAR isolated from co-culture established in hypoxia (1.5%O2) a day before initiation of treatment with IM for 48h (E-G) or FACS-sorted K562/luc GFP positive cells from xenografts (H) . (E-F,H) Percentage of parental live cell subpopulations that are: double positive for CD45 and CD235a (CD235a&CD45), positive only for CD45, or only for CD235a, or negative for both CD markers. Representative scatter plots in (E) , summary of independent co-culture experiments (n=4) in (F) . (G) Fluorescence intensity of surface CD36 protein staining in the fraction of cells positive for CD235a or CD45. Numbers correspond to fold change in shTIAR to shNEG ± ME (n=2). (H) Percent GFP and hCD45-positive cells from different xenografts (n=4) that are positive for CD235a. Two-way ANOVA test was used to for comparison of shNEG_C to other variants (@), and p=0.0046.

    Article Snippet: Human chronic myeloid leukemia cell line K562 (#CCL-243) and bone marrow stroma fibroblast cell line HS-5 (#CRL-11882) were obtained from American Type Culture Collection (USA); human chronic myeloid leukemia cell line LAMA-84 (#ACC 168) was from DSMZ.

    Techniques: Expressing, Cell Culture, Western Blot, Membrane, Control, Flow Cytometry, Fluorescence, Cell Differentiation, Isolation, Co-Culture Assay, Staining, Comparison